Diagnostic Value of Glypican-1; a New Marker Differentiating Pulmonary Squamous Cell Carcinoma from Adenocarcinoma: Immunohistochemical Study on Egyptian Series

Overview

Journal Clin Exp Med

Date 2025 Jan 11

PMID 39797955

Authors

Iman Adel

Heba A Mahmoud

Amira Ismail Khater

Fatma S Hafez

Affiliations

Soon will be listed here.

Abstract

Lung cancer is one of the major causes of cancer morbidity and mortality. Subtyping of non-small cell lung cancer is necessary owing to different treatment options. This study is to evaluate the value of immunohistochemical expression of glypican-1 in the diagnosis of lung squamous cell carcinoma (SCC). This retrospective study included a total of 68 cases, of which 36 were diagnosed as SCC and 32 as adenocarcinoma (ADC). Furthermore, glypican-1 expression was compared with the expressions of p63, thyroid transcription factor-1 (TTF-1), and napsin A. All cases of SCC except one showed positive immunostaining to glypican-1; 35/36 (97.2%) cases, and predominantly scored 3 + . While only 5 cases of ADC showed positive immunostaining to glypican-1, having a score of 1 + or 2 + . The difference between glypican-1 expression of the two tumor types was highly significant (p value < 0.001). The sensitivity, specificity, and overall accuracy of glypican-1 expression for differentiating lung SCC from ADC were 97.2%, 84.4%, and 91.2%, respectively. The sensitivity of glypican-1 is more than p63 in the diagnosis of lung SCC. Glypican-1 can be added as a new diagnostic marker to help in the accurate discrimination between poorly differentiated lung SCC and solid predominant adenocarcinoma cases.

References

Dearden S, Stevens J, Wu Y, Blowers D . Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013; 24(9):2371-6. PMC: 3755331. DOI: 10.1093/annonc/mdt205. View

Harada E, Serada S, Fujimoto M, Takahashi Y, Takahashi T, Hara H . Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma. Oncotarget. 2017; 8(15):24741-24752. PMC: 5421884. DOI: 10.18632/oncotarget.15799. View

Li N, Gao W, Zhang Y, Ho M . Glypicans as Cancer Therapeutic Targets. Trends Cancer. 2018; 4(11):741-754. PMC: 6209326. DOI: 10.1016/j.trecan.2018.09.004. View

Conde E, Angulo B, Redondo P, Toldos O, Garcia-Garcia E, Suarez-Gauthier A . The use of P63 immunohistochemistry for the identification of squamous cell carcinoma of the lung. PLoS One. 2010; 5(8):e12209. PMC: 2923180. DOI: 10.1371/journal.pone.0012209. View

Zhang Z, Coomans C, David G . Membrane heparan sulfate proteoglycan-supported FGF2-FGFR1 signaling: evidence in support of the "cooperative end structures" model. J Biol Chem. 2001; 276(45):41921-9. DOI: 10.1074/jbc.M106608200. View

Kenfield S, Wei E, Stampfer M, Rosner B, Colditz G . Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control. 2008; 17(3):198-204. PMC: 3044470. DOI: 10.1136/tc.2007.022582. View

Chen G, Wu H, Zhang L, Wei S . High glypican-1 expression is a prognostic factor for predicting a poor clinical prognosis in patients with hepatocellular carcinoma. Oncol Lett. 2020; 20(5):197. PMC: 7491109. DOI: 10.3892/ol.2020.12058. View

Fabregat I, Fernando J, Mainez J, Sancho P . TGF-beta signaling in cancer treatment. Curr Pharm Des. 2013; 20(17):2934-47. DOI: 10.2174/13816128113199990591. View

Su G, Meyer K, Nandini C, Qiao D, Salamat S, Friedl A . Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells. Am J Pathol. 2006; 168(6):2014-26. PMC: 1606624. DOI: 10.2353/ajpath.2006.050800. View

10.

Cross M, Claesson-Welsh L . FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 2001; 22(4):201-7. DOI: 10.1016/s0165-6147(00)01676-x. View

11.

Wang M, Herbst R, Boshoff C . Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021; 27(8):1345-1356. DOI: 10.1038/s41591-021-01450-2. View

12.

Amatya V, Kushitani K, Kai Y, Suzuki R, Miyata Y, Okada M . Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Mod Pathol. 2018; 31(5):809-815. DOI: 10.1038/modpathol.2017.190. View

13.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

14.

Meza R, Meernik C, Jeon J, Cote M . Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010. PLoS One. 2015; 10(3):e0121323. PMC: 4379166. DOI: 10.1371/journal.pone.0121323. View

15.

Munekage E, Serada S, Tsujii S, Yokota K, Kiuchi K, Tominaga K . A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. Neoplasia. 2021; 23(9):939-950. PMC: 8340053. DOI: 10.1016/j.neo.2021.07.006. View

16.

Lu H, Niu F, Liu F, Gao J, Sun Y, Zhao X . Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma. Cancer Med. 2017; 6(6):1181-1191. PMC: 5463070. DOI: 10.1002/cam4.1064. View

17.

Pao W, Girard N . New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011; 12(2):175-80. DOI: 10.1016/S1470-2045(10)70087-5. View

18.

Yatabe Y, Dacic S, Borczuk A, Warth A, Russell P, Lantuejoul S . Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. J Thorac Oncol. 2018; 14(3):377-407. PMC: 6422775. DOI: 10.1016/j.jtho.2018.12.005. View

19.

Thai A, Solomon B, Sequist L, Gainor J, Heist R . Lung cancer. Lancet. 2021; 398(10299):535-554. DOI: 10.1016/S0140-6736(21)00312-3. View

20.

Kai Y, Amatya V, Kushitani K, Kambara T, Suzuki R, Fujii Y . Glypican-1 is a novel immunohistochemical marker to differentiate poorly differentiated squamous cell carcinoma from solid predominant adenocarcinoma of the lung. Transl Lung Cancer Res. 2021; 10(2):766-775. PMC: 7947391. DOI: 10.21037/tlcr-20-857. View